Answers are grounded in this paper and cite their sources.
Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: